STEROID COMPOUND FOR USE IN TREATMENT OF HEPATIC ENCEPHALOPATHY Russian patent published in 2019 - IPC A61K31/568 A61P25/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine, particularly to use of compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime or a pharmaceutically acceptable salt thereof, as well as to a method of treating hepatic encephalopathy. Group of inventions relates to use of compound 3α-ethynyl-3β-hydroxyandrostan-17-one oxime or a pharmaceutically acceptable salt thereof for preparing a medicinal agent for treating hepatic encephalopathy. Also described is a method of treating hepatic encephalopathy, comprising administering a pharmaceutically effective amount of 3α-ethynyl-3β-hydroxyandrostan-17-one oxime or a pharmaceutically acceptable salt thereof to a patient in need thereof.

EFFECT: group of inventions enables selective inhibition of positive modulation of GABA_A receptor with endogenous steroids when administering 3α-ethynyl-3β-hydroxyandrostan-17-one oxime, and 3α-ethynyl-3β-hydroxyandrostan-17-one oxime can have a positive effect on motor and cognitive impairment in hepatic encephalopathy.

28 cl, 14 dwg, 1 tbl, 13 ex